Introduction Not too long ago, Lupron Depot®(leuprolide acetate), an injectable
gonadotropin-releasing hormone (GnRH) agonist, was the only Food and Drug …

OBJECTIVE: To investigate the noninferiority of relugolix compared with leuprorelin acetate
in reducing heavy menstrual bleeding associated with uterine leiomyomas. METHODS: In a …

Background Uterine leiomyomas are common for reproductive-aged women and affect
women's quality of life due to heavy menstrual bleeding or dysmenorrhea. Leiomyomas …

Background Uterine leiomyomas are the most common neoplasm affecting women and
frequently cause heavy menstrual bleeding and pain. Gonadotropin-releasing hormone …

Objective To review data of elagolix plus estradiol and norethindrone acetate as add-back
therapy for the treatment of heavy menstrual bleeding (HMB) in premenopausal women with …

ABSTRACT Introduction Uterine fibroids (UFs) are the most common benign tumor arising
from myometrium of reproductive age women, with significant financial burden estimated in …

OBJECTIVE: In the LIBERTY 1 and LIBERTY 2 placebocontrolled trials, once-daily relugolix
combination therapy reduced menstrual blood loss volume and pain in women with heavy …

OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-
releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in …

Limited pharmacological treatments for uterine leiomyomata (fibroids) are available. Now,
two phase III trials lasting 24 weeks showed marked reduction in leiomyoma-related heavy …

Eighty percent of patients will develop uterine leiomyomas before age 50 years,
approximately a third of which will be symptomatic. They typically present with heavy …